MLANA and melanoma: CD4 clones derived from cancer patients resulted to be regulatory cells and to recognize peptides derived from TAAs, such as LAGE1 (92), ARTC1 (93), TRAG-3, NY-ESO-1 (94–, 96), Melan-A (97), survivin, TRP1, and gp100 (94) in melanoma patients, and WT-1 in leukemia patients (98).